Fate Therapeutics' FT819 shows renal response in two lupus nephritis patients at six months in Phase 1 trial

• Fate Therapeutics announced preliminary Phase 1 results for FT819 in lupus nephritis, presented October 24, 2026, at ASN Kidney Week.
• Both patients evaluable at six months on the selected bendamustine regimen achieved renal responses, with improvements in kidney damage.
• No dose-limiting toxicities occurred among 29 autoimmune patients, supporting outpatient administration.
• The findings support the ongoing, potentially registrational Phase 2 RECLAIM-LN trial in refractory, moderate-to-severe lupus with kidney involvement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fate Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610260700PRIMZONEFULLFEED9852835) on October 26, 2026, and is solely responsible for the information contained therein.